Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

119.93
Delayed Data
As of Aug 28
 +6.08 / +5.34%
Today’s Change
43.86
Today|||52-Week Range
121.70
+64.04%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$21.6B

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
1801 Augustine Cut-Off
Wilmington Delaware 19803
P:(302) 498-6700
Investor Relations:
(302) 498-5914

Employees

Shareholders

Mutual fund holders62.63%
Other institutional33.14%
Individual stakeholders11.88%

Top Executives

Hervé HoppenotPresident, Chief Executive Officer & Director
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Richard S. LevyChief Drug Development Officer & Executive VP